Redeye provides an update following Guard Therapeutics’ announcement of new encouraging results from its phase IIa study AKITA. The data from secondary analyses further strengthen the rationale for RMC-035, leading us to increase our expectations of success for the phase IIb study POINTER, for which topline data are expected in early November. Our adjustments lead to an increased valuation.
LÄS MER
